http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2380378-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a37e62709117581f13c896797c65567f |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10 |
| filingDate | 2005-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2010-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b46b0d26947aaaa7cb01ef77b326d56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64397019eeb0135a95c3b5cd04e5c212 |
| publicationDate | 2010-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2380378-C2 |
| titleOfInvention | Antibody or fragment thereof with hiv-neutralising activity |
| abstract | FIELD: medicine. n SUBSTANCE: there is described anti-HIV monoclonal antibody that identifies a peptide with a sequence SEQ ID NO 7, or analogue thereof where the region specifying complementarity 3 (CDR3) of variable region of H-(heavy) chain, contains SEQ ID NO 1, or functional analogue thereof. There is described variable region of H-chain specifying SEQ ID NO 7, or its analogue where CDR 3 contains SEQ ID NO 1, or functional analogue thereof. There is presented nucleic acid molecule coding the described antibody. There is offered expression vector containing specified nucleic acid. There is offered host-cell transformed by specified nucleic acid molecule or offered vector. There is disclosed anti-HIV pharmaceutical composition containing the effective amount of described antibody or specified nucleic acid molecule, offered vector or host-cell. There is offered method for passive immunotherapy of an individual susceptible to HIV infection that involves introduction to said individual of described antibody or functional fragment thereof in therapeutically effective amount. There is also offered method for detection in vitro of HIV strains in a sample that involves the stage of bringing the sample in contact to described antibody or functional fragment thereof. n EFFECT: invention allows neutralising HIV infection, reducing infection through mucous membranes and performing passive immunotherapy. n 18 cl, 8 dwg, 1 tbl, 6 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2757135-C2 |
| priorityDate | 2005-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 308.